Menopause - Abstract: Volume 14(6) November December 2007 p 995-998 Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
14(6):995-998, Nov Dec 2007. Bender, Catherine M. MD 3 Abstract: Objective: Hormones own been implicated as modulators of cognitive functioning. For instance, results of our preceding assignment in women with breast cancer showed that cognitive impairment was aggrandized severe and involved extra recapture domains in those who received adjuvant tamoxifen therapy compared with women who received chemotherapy alone or no adjuvant therapy.
Recently aromatase inhibitors such as anastrozole posses been used in lieu of tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor-positive, early-stage breast cancer. Plasma oestrogen levels are significantly lower in women who come by anastrozole compared with those who grip tamoxifen.
We hypothesized, therefore, that anastrozole would admit a and profound development on cognitive advantage than tamoxifen, a mixed estrogen agonist antagonist. Design: To analysis this speculation we compared cognitive supply in women with early-stage breast cancer who received tamoxifen with those who received anastrozole therapy in a cross-sectional study.
We evaluated cognitive function, depression, anxiety, and exhaustion in 31 postmenopausal women with early-stage breast cancer who were between the ages of 21 and 65 senescence and treated with tamoxifen or anastrozole for a minimum of 3 months. Results: The results showed that women who received anastrozole had poorer verbal and visual learning and recall than women who received tamoxifen.
Conclusions: Additional, prospective studies are needed to validate and confirm the changes in cognitive service associated with hormone therapy for breast cancer. All rights reserved.
